Alport syndrome differential diagnosis

Revision as of 17:24, 31 October 2013 by Rim Halaby (talk | contribs)
Jump to navigation Jump to search

Alport syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Alport syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Echocardiography or Ultrasound

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alport syndrome differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alport syndrome differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alport syndrome differential diagnosis

CDC on Alport syndrome differential diagnosis

Alport syndrome differential diagnosis in the news

Blogs on Alport syndrome differential diagnosis

Directions to Hospitals Treating Alport syndrome

Risk calculators and risk factors for Alport syndrome differential diagnosis

The differential diagnosis of Alport’s syndrome includes other conditions that involve persistent familial hematuria, renal failure, hearing loss, retinal fleck, and lamellated GBM (23349312). Some of the other diseases are listed in the table below.[1][2][3][4][5]

         Normal  0          false  false  false    EN-US  JA  X-NONE

According to expert opinion[6], the differential diagnosis of Alport’s syndrome is very wide and includes the following:

Familial hematuria[6]:

  • TBMN
  • Familial IgA nephropathy
  • MYH9-related disorder, such as Fechtner and Epstein syndromes
  • Membranoproliferative GN type 2
  • Familail hemolytic uremic syndrome
  • C3 nephropathy
  • ADPKD
  • Sickle cell disease or trait
  • Familial hypercalciuria or familial urolithiasis
  • Renal impairment and hearing loss (23349312):
  • MYH-9 related disorders such as Fechtner syndrome
  • Nephronophthisis
  • Bartter syndrome
  • Distal renal tubular acidosis
  • MELAS syndrome
  • Fabry disease
  • Branchio-oto-renal syndrome
  • Townes-Brock syndrome
  • CHARGE syndrome
  • Kallmann syndrome
  • Alstrom disease
  • Muckle-Wells syndrome

Hearing loss[6]

  • Middle-ear infections
  • Age
  • Industrial noise exposure
  • Ototoxic drugs
  • Renal failure and dialysis
  • Retinal flecks (23349312):
  • Membranoproliferative GN type 2
  • IgA nephropathy
  • Systemic lupus erythematosus
  • Other forms of GN
  • Severe hypertension
  • C3 nephropathy

Lamellated GBM[6]:

  • Focal damage
  • MYH9-related disorders, such as Fechtner and Epstein syndromes
  • Pierson syndromeNail-patella syndromeMutations in the tetraspanin (CD151) gene
  • Frasier syndrome
  • Galloway-Mowat syndrome

References

  1. Hudson BG, Reeders ST, Tryggvason K (1993). "Type IV collagen: structure, gene organization, and role in human diseases. Molecular basis of Goodpasture and Alport syndromes and diffuse leiomyomatosis". J Biol Chem. 268 (35): 26033–6. PMID 8253711.
  2. Amari F, Segawa K, Ando F (1994). "Lens coloboma and Alport-like glomerulonephritis". Eur J Ophthalmol. 4 (3): 181–3. PMID 7819734.
  3. Lonsdale RN, Roberts PF, Vaughan R, Thiru S (1992). "Familial oesophageal leiomyomatosis and nephropathy". Histopathology. 20 (2): 127–33. PMID 1559666.
  4. García-Torres R, Orozco L (1993). "Alport-leiomyomatosis syndrome: an update". Am J Kidney Dis. 22 (5): 641–8. PMID 8238008.
  5. McCarthy PA, Maino DM (2000). "Alport syndrome: a review". Clin Eye Vis Care. 12 (3–4): 139–150. PMID 11137428.
  6. 6.0 6.1 6.2 6.3 Savige J, Gregory M, Gross O, Kashtan C, Ding J, Flinter F (2013). "Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy". J Am Soc Nephrol. 24 (3): 364–75. doi:10.1681/ASN.2012020148. PMID 23349312.

Template:WH Template:WS